Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Solasia Pharma KK ( (JP:4597) ) has provided an announcement.
Solasia Pharma has signed a license agreement granting MAAB Pharma exclusive marketing and manufacturing rights for its antiemetic patch Sancuso in mainland China, Hong Kong, Macau and Taiwan, as part of a restructuring of its sales framework in the region. After the current commercialization agreement with Lee’s Pharmaceutical in mainland China expires at the end of 2026, sales activities will transfer to MAAB, which plans to establish local production to lower costs, while Solasia will receive staged contract payments tied to the business transfer and future royalties on sales, positioning MAAB as a key strategic partner for Solasia’s broader China business and potentially improving the product’s competitiveness and profitability in that market.
The most recent analyst rating on (JP:4597) stock is a Hold with a Yen29.00 price target. To see the full list of analyst forecasts on Solasia Pharma KK stock, see the JP:4597 Stock Forecast page.
More about Solasia Pharma KK
Solasia Pharma K.K. is a Tokyo-based specialty pharmaceutical company focused on oncology-related treatments, including supportive care products for cancer patients. One of its key products in Asia is Sancuso, a transdermal granisetron patch designed to prevent chemotherapy-induced nausea and vomiting, with a particular market focus on patients who struggle with oral antiemetic medications and outpatient chemotherapy settings in the Greater China region.
Average Trading Volume: 42,185,853
Technical Sentiment Signal: Sell
Current Market Cap: Yen8.06B
For a thorough assessment of 4597 stock, go to TipRanks’ Stock Analysis page.